Universität zu Köln

Wolber, Philipp, Nachtsheim, Lisa, Hoffmann, Franziska ORCID: 0000-0002-6872-924X, Klussmann, Jens Peter ORCID: 0000-0002-8223-7954, Meyer, Moritz, von Eggeling, Ferdinand ORCID: 0000-0002-8062-6999, Guntinas-Lichius, Orlando ORCID: 0000-0001-9671-0784, Quaas, Alexander and Arolt, Christoph (2021). Trophoblast Cell Surface Antigen 2 (Trop-2) Protein is Highly Expressed in Salivary Gland Carcinomas and Represents a Potential Therapeutic Target. Head Neck Pathol., 15 (4). S. 1147 - 1156. NEW YORK: SPRINGER. ISSN 1936-0568

Full text not available from this repository.

Abstract

Treatment options for unresectable, recurrent or metastatic salivary gland carcinomas (SGC) are scarce. Trophoblast cell surface antigen 2 (Trop-2) is a transmembrane glycoprotein that is involved in a variety of oncogenic cell signaling pathways. Its potential as a target for the antibody-drug conjugate sacituzumab govitecan has already been demonstrated in different tumor entities. The United States Food and Drug Administration approved this antibody-drug conjugate for the treatment of metastatic triple-negative breast cancer. Here, we aimed to investigate Trop-2 protein expression in different entities of SGCs. We retrospectively reviewed the medical records of all patients that underwent surgery for a primary SGC in a tertiary referral center between 1990 and 2014. Immunohistochemical (IHC) staining for Trop-2 was performed and rated as negative, weak, moderate or high using a semiquantitative score. Additionally, representative cases were analyzed using MALDI-mass spectrometry (MS) imaging to confirm the IHC results. The cohort consisted of 114 tumors of the parotid gland (90.4%) and submandibular gland (9.6%). It mainly included mucoepidermoid, salivary duct and adenoid cystic carcinomas. In IHC samples, 44% showed high, 38% moderate and 10% weak expression rates of Trop-2. MALDI-MS imaging confirmed the presence of Trop-2 protein in 80% of the tested tumor samples. This is the first study to demonstrate that several types of SGC express Trop-2 with variable intensity. Since there are currently few systemic treatment options for advanced SGCs, Trop-2 represents a promising target for further clinical studies, for instance, with sacituzumab govitecan.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Wolber, Philipp UNSPECIFIED UNSPECIFIED UNSPECIFIED Nachtsheim, Lisa UNSPECIFIED UNSPECIFIED UNSPECIFIED Hoffmann, Franziska UNSPECIFIED orcid.org/0000-0002-6872-924X UNSPECIFIED Klussmann, Jens Peter UNSPECIFIED orcid.org/0000-0002-8223-7954 UNSPECIFIED Meyer, Moritz UNSPECIFIED UNSPECIFIED UNSPECIFIED von Eggeling, Ferdinand UNSPECIFIED orcid.org/0000-0002-8062-6999 UNSPECIFIED Guntinas-Lichius, Orlando UNSPECIFIED orcid.org/0000-0001-9671-0784 UNSPECIFIED Quaas, Alexander UNSPECIFIED UNSPECIFIED UNSPECIFIED Arolt, Christoph UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-583439
DOI:	10.1007/s12105-021-01325-5
Journal or Publication Title:	Head Neck Pathol.
Volume:	15
Number:	4
Page Range:	S. 1147 - 1156
Date:	2021
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1936-0568
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language Pathology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/58343